abbv-383
abbvie
abbv383: responses &gt;50% and brisk &lt;1m; dor and pfs encouraging in heavily pretreated #myeloma group. supports continued evaluation. results will be published in jco #ims2022 #mmsm 
Hematology is in my blood. Posts are mine. Mayo Clinic MM RN Navigator, IMF MM KOL, educator, patient advocate, medical writer.